Tech Spotlight: Peptide-Based Vaccines for Influenza, SARS, HIV and Ebola Viruses

By studying the SARS virus, researchers led by Drs. Kathryn Holmes and Robert Hodges of the University of Colorado have developed a novel vaccine strategy that inhibits Type I viral infections with broad application for vaccines to other viruses of this group. The peptides used by Drs. Holmes and Hodges can be easily and rapidly synthesized, and can be used to prepare an active vaccine or a passive vaccine (antibody therapeutic) for humans.

While this technology was initially develop for the SARS epidemic, recent efforts have been directed at illustrating its efficacy with Influenza virus. Viral challenge experiments are currently in progress to demonstrate that this strategy will work to immunize against the flu virus - initial in vivo passive immunization data are positive, with final results expected in Summer 2009.

To read a non-confidential summary of this technology, please click the image above. For more CU technologies available for licensing, please visit our Tech Explorer site.